Novo Nordisk can add data showing Tresiba can reduce the risk of hypoglycaemia to its label, a development which should help its fight competition from cheaper alternati
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.